Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

58.23 +0.32 (+0.55%)
Official Closing Price Updated: 4:10 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,923,145
Open 58.10
Bid (Size) 58.20 (1)
Ask (Size) 58.99 (2)
Prev. Close 57.91
Today's Range 57.80 - 58.25
52wk Range 31.80 - 60.20
Shares Outstanding 170,341,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
From Catalent, Inc.
Via Business Wire
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves. 
Via Benzinga

Performance

YTD
+29.26%
+29.26%
1 Month
+3.06%
+3.06%
3 Month
+3.89%
+3.89%
6 Month
+16.88%
+16.88%
1 Year
+21.46%
+21.46%

More News

Read More
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Catalent Stockholders Approve Transaction with Novo Holdings
From Catalent, Inc.
Via Business Wire
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
Via Benzinga
(CTLT) - Analyzing Catalent's Short Interest
Via Benzinga
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Via The Motley Fool
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Via Benzinga
CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
Via InvestorPlace
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
From Catalent, Inc.
Via Business Wire
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Via Benzinga
Robbins LLP Reminds Stockholders it is Investigating the Acquisition of Catalent, Inc. (CTLT)
From Robbins LLP
Via Business Wire
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Via Benzinga
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
From Robbins LLP
Via GlobeNewswire
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
Via The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Did Novo Nordisk Just Get a Jump on Eli Lilly?
Via The Motley Fool
Exposures Product Safety
The Top 3 Pharma Stocks to Buy in March2024
Via InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
Via Benzinga
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
From Catalent, Inc.
Via Business Wire
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Via Benzinga
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Via The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.